Market Place
Sourcing Support
Samsung Bioepis`s Biologic Epysqli Receives Suppl Approval in US
15 Nov 2024 //
FDA
Samsung Gets Positive CHMP Opinion for Denosumab Biosimilars
15 Nov 2024 //
GLOBENEWSWIRE
Samsung Bioepis Q4 2024 US Biosimilar Market Report Released
10 Oct 2024 //
GLOBENEWSWIRE
FDA Issues Form 483 to Samsung Bioepis Co., Ltd.
25 Sep 2024 //
FDA
Samsung Bioepis Presents Data On EPYSQLI At European Society
23 Sep 2024 //
GLOBENEWSWIRE
Samsung Bioepis and Biogen Receive Positive CHMP
20 Sep 2024 //
GLOBENEWSWIRE
Samsung Bioepis`s Eksunbi (ustekinumab) Receives Approval in Europe
12 Sep 2024 //
EMA
Samsung Biologics Reports Record Quarter Due To Biosimilar Sales
24 Jul 2024 //
FIERCE PHARMA
FDA Approves Samsung Bioepis` EPYSQLI As Biosimilar To Soliris
22 Jul 2024 //
GLOBENEWSWIRE
Samsung Bioepis`s Biologic Epysqli (Eculizumab) Receives Approval in US
19 Jul 2024 //
FDA
AbbVie`s Humira loses some ground in high-stakes battle against biosimilars
12 Jul 2024 //
FIERCE PHARMA
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
11 Jul 2024 //
GLOBENEWSWIRE
Samsung Bioepis’ PYZCHIVA Approved by FDA as Biosimilar of Stelara
01 Jul 2024 //
CONTRACT PHARMA
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar
01 Jul 2024 //
GLOBENEWSWIRE
Samsung Bioepis Releases 2024 Sustainability Report on Accessibility and R&D
25 Jun 2024 //
GLOBENEWSWIRE
Samsung Bioepis Presents EPYSQLI Post-Hoc Analysis At EHA
14 Jun 2024 //
GLOBENEWSWIRE
Italy starts probe into Lucentis biosimilar delay allegation
08 Jun 2024 //
PHARMAPHORUM
Novartis, Roche unit and others face Italy antitrust probe over eye drug
07 Jun 2024 //
REUTERS
Samsung Bioepis Eculizumab Biosimilar EPYSQLI Post-Hoc Analysis At EHA
30 May 2024 //
GLOBENEWSWIRE
Samsung Biosimilar Sb16 Prolia: Switching Period Results At Ects 2024
27 May 2024 //
GLOBENEWSWIRE
Samsung Bioepis` Eticovo (etanercept-ykro) Receives Suppl Approval in U.S.
03 May 2024 //
FDA
Samsung Bioepis Releases Second Quarter 2024 US Biosimilar Market Report
08 Apr 2024 //
GLOBENEWSWIRE
Samsung Bioepis Initiates Ph 3 Trial for SB27, Proposed Biosimilar to Keytruda
05 Apr 2024 //
GLOBENEWSWIRE
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio
09 Mar 2024 //
GLOBENEWSWIRE
Samsung Bioepis Releases First Quarter 2024 US Biosimilar Market Report
17 Jan 2024 //
GLOBENEWSWIRE
Samsung Bioepis Secures US License Date for SB17
30 Nov 2023 //
GLOBENEWSWIRE
J&J, Samsung Bioepis ink Stelara biosimilar settlement
30 Nov 2023 //
FIERCE PHARMA
Samsung Bioepis & Organon Announce Acceptance of sBLA for Interchangeability Designation for HADLIMA
07 Nov 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Phase 1 and 3 Clinical Results for SB16
15 Oct 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Two Abstracts at EADV 2023 Congress
11 Oct 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Clinical Trial for SB15
07 Oct 2023 //
GLOBENEWSWIRE
Sandoz inks deal to commercialize biosim to J&J`s Stelara
12 Sep 2023 //
FIERCE PHARMA
Samsung Bioepis looks to acquire Biogen`s biosim unit: reports
03 Aug 2023 //
FIERCE PHARMA
Samsung Bioepis & Organon Announce Results from Study of SB5 Humira Biosimilar
01 Aug 2023 //
GLOBENEWSWIRE
Samsung`s Biologic Hadlima (Adalimumab) Receives Approval in the U.S.
11 Jul 2023 //
FDA
Samsung Bioepis Releases its Second US Biosimilar Market Report
11 Jul 2023 //
GLOBENEWSWIRE
Organon, Samsung launch copycat for arthritis drug Humira at 85% discount
03 Jul 2023 //
REUTERS
Samsung Bioepis Releases 2023 Sustainability Report
30 Jun 2023 //
GLOBENEWSWIRE
Samsung`s Biologic Byooviz (Ranibizumab) Receives Approval in the U.S.
16 Jun 2023 //
FDA
Samsung Bioepis`s Epysqli (Eculizumab) Receives Approval in the Europe
31 May 2023 //
EMA
European Commission approves haematology biosimilar
30 May 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
1-Year Outcomes of PIII Study for SB15, Proposed biosimilar to Eylea, Presented
24 Apr 2023 //
GLOBENEWSWIRE
Samsung Bioepis to Present New Data for SB15, biosimilar to Eylea (aflibercept)
20 Apr 2023 //
GLOBENEWSWIRE
Samsung Bioepis Releases its First US Biosimilar Market Report
17 Apr 2023 //
GLOBENEWSWIRE
Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar
31 Mar 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Phase 1 Study Results of SB17 (Ustekinumab)
17 Mar 2023 //
GLOBENEWSWIRE
Samsung Announces Health Canada Approval of Citrate-Free High-Concn. of HUMIRA
03 Jan 2023 //
GLOBENEWSWIRE
Samsung Bioepis speeding up US launch of Humira biosimilar
01 Jan 2023 //
KOREAHERALD
Samsung`s Biologic Hadlima (Adalimumab) Receives Approval in the U.S.
23 Dec 2022 //
FDA
Samsung Bioepis Presents Data from its Ophthalmology Biosimilar Portfolio
27 Sep 2022 //
GLOBENEWSWIRE
Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5
07 Sep 2022 //
GLOBENEWSWIRE
Samsung Bioepis, Organon Bag FDA Approval of Humira Biosimilar, HADLIMA
17 Aug 2022 //
BUSINESSWIRE
Samsung`s Biologic Byooviz (Ranibizumab-Nuna) Receives Approval in the U.S.
15 Aug 2022 //
FDA
Samsung`s Biologic Hadlima (Adalimumab-Bwwd) Receives Approval in the U.S.
15 Aug 2022 //
FDA
Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab)
09 Jun 2022 //
GLOBENEWSWIRE
Changes Afoot in US AMD Market as Prescribers Brace for the Launch of Byooviz
08 Jun 2022 //
PRNEWSWIRE
Biogen launch first US biosimilar with Samsung Bioepis
03 Jun 2022 //
FIERCEPHARMA
Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at EULAR 2022
31 May 2022 //
GLOBENEWSWIRE
